Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cadisegliatin · TTP399, NN-9108

Small molecule · Activator of glucokinase (GCK) · developed by vTv Therapeutics

Phase 3 Most advanced trial
VTVT Developer
3 Registered trials

What is Cadisegliatin?

Cadisegliatin is an orally bioavailable small-molecule glucokinase activator that acts as an adjunct to insulin. It is studied in type 1 and type 2 diabetes mellitus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TTP399, NN-9108, NNC 0080-0000-3315
Drug type
Small molecule
Targets
glucokinase (GCK)
Mechanism
Activator of glucokinase (GCK)
Pathways
glucose metabolism
Therapy area
Endocrine, Metabolic
Developer
vTv Therapeutics (VTVT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
98S8SH8UNF

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06334133 Phase 3 Diabetes Mellitus, Type 1 Active not recruiting VTVT
NCT03335371 Phase 1/2 Diabetes Mellitus, Type 1 Completed VTVT
NCT02405260 Phase 2 Diabetes Mellitus, Type 2 Completed VTVT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2

More from vTv Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VTVT page.

Follow VTVT, the company behind Cadisegliatin

See VTVT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VTVT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.